

CLINICAL RESEARCH STUDY

New Emory clinical study offers hope to heart attack patients

On the forefront of research and medical discovery, Emory University School of Medicine is offering hope to heart attack victims with a new clinical study. The clinical study uses stem cells generated within the bone marrow to grow new blood vessels to improve circulation around the heart and enhance its function. The Emory team is committed to finding innovative solutions to improve the quality of life for heart attack victims. This revolutionary approach to treating acute myocardial infarction restores the function of damaged heart muscle.

Eligibility:

Forty men and women who have suffered from an acute myocardial infarction within the last five days of starting treatment will be asked to participate in the study. Twenty patients will be randomly selected by computer to receive bone marrow cells and 20 will be placed in a control group that does not receive the cells. Patients in the study will be followed closely for the first year after cell infusion and then at regular intervals over a five-year period.

Clinical Research:

Emory researchers, led by Arshed Quyyumi, MD, professor of cardiology at Emory University School of Medicine, and cardiology fellow Veerappan Subramaniam, MD, found that treatment with the growth factor GM-CSF increased total white blood cell count and the total number of circulating endothelial progenitor cells. Patients who received the growth factor therapy also experienced an improvement in the ability to walk without pain.

Upcoming Clinical Study:

In a Phase I/II clinical study, physicians will harvest stem cells from patients' bone marrow and use a cell separation technique to isolate an enriched population containing a



high number of progenitor cells. The cells will be reinfused into the patients through cardiac catheterization. The study will determine whether providing a concentrated quantity of these specialized cells can improve heart muscle function. The study will also test different doses of the stem cell therapy to determine which dose is most effective.

Research Team:

As one of only three centers in the nation to perform this procedure, the Emory School of Medicine, led by cardiologist Arshed Quyyumi, MD, and Emory Winship Cancer Institute hematologist and oncologist Edmund Waller, MD, PhD, continues to make great strides in cardiovascular clinical research with this study.

Locations:

The trial is taking place at Emory University Hospital and at Emory Crawford Long Hospital in Midtown. Patients who received their initial heart attack treatment at other facilities also may enroll in the study.

To find out more about the study and eligibility, call 404-783-5908.

EMORYHEALTHCARE

EMORY HEART & VASCULAR CENTER


Advancing the Possibilities®

www.emoryhealthcare.org

DIRECTORS:


Arshed Quyyumi, MD, FACC
phone 404-727-3655 fax 404-712-8785
Board Certified: Internal Medicine, Cardiology
Clinical Interests: Cardiology research, general cardiology and prevention

Edmund Waller, MD, PhD, FACC
phone 404-778-1900 fax 404-778-1936
Board Certified: Internal Medicine, Medical Oncology
Clinical Interests: Bone marrow transplant, hematology/ oncology, hematopoietic syndrome



Emory Crawford Long Hospital
550 Peachtree Street, NE
Atlanta, Georgia 30308

Valet parking is available at the Medical Office Tower main entrance. Deck parking is available beside the Medical Office Tower.



Emory University Hospital
1364 Clifton Road, NE
Atlanta, Georgia 30322

Valet parking is available at the hospital main entrance. Deck parking is available behind The Emory Clinic, Building B.



EMORY HEART & VASCULAR CENTER

Advancing the Possibilities®

www.emoryhealthcare.org